Methotrexate Use in Pregnancy Termination

Critical Considerations

The American Academy of Dermatology and other medical societies recommend that methotrexate is absolutely contraindicated for elective pregnancy termination in women with certain medical conditions, and this principle applies to pregnancy of unknown location (PUL) when the intent is termination of an undesirable but potentially viable intrauterine pregnancy 1, 2
The American College of Emergency Physicians states that methotrexate is FDA-approved and guideline-supported only for treating ectopic pregnancy, not for elective termination of intrauterine pregnancy 3, 4, 5

The American College of Emergency Physicians recommends that methotrexate is appropriate for hemodynamically stable patients with confirmed or highly suspected ectopic pregnancy 3, 4, 6
The treatment guidelines suggest that methotrexate is suitable for ectopic mass ≤3.5 cm in greatest dimension, β-hCG levels preferably ≤5,000 mIU/mL, and no embryonic cardiac activity on ultrasound 6
The standard dosing for methotrexate in ectopic pregnancy is 50 mg/m² intramuscular injection 3, 4, 5

The use of methotrexate in PUL carries a 23% risk of miscarriage, a 3.4-fold increased risk of cardiovascular defects, and a 2.6-fold increased risk of oral clefts 7, 8
Methotrexate use in PUL can result in multiple congenital anomalies, including cardiac, skeletal, and central nervous system defects 1, 2

The American College of Emergency Physicians advises that if the pregnancy is undesirable, the location of the pregnancy should be established definitively before treatment 3, 4, 5
If ectopic pregnancy is confirmed, methotrexate becomes an appropriate medical option, but if intrauterine pregnancy is confirmed, methotrexate is contraindicated for elective termination 3, 4, 6

The treatment failure rates with methotrexate for ectopic pregnancy range from 3-36%, with rupture occurring in 0.5-19% of cases 4, 5, 6
If methotrexate is inadvertently given during an intrauterine pregnancy, it should be discontinued, and high-dose folic acid supplementation should be initiated, with referral for obstetric counseling 7, 8